Allergy Therapeutics flags positive outcomes from recent treatment trial
By Josh White
Date: Monday 20 May 2019
(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive Phase 1 safety and tolerability results of subcutaneous \'Acarovac MPL\' (monophosphoryl lipid A) in patients with house dust mite-induced allergic rhinoconjunctivitis on Monday.
The AIM-traded firm said the AM101 trial was an open-label study to assess the safety and tolerability of Acarovac MPL in 16 adult patients with house dust mite-mediated allergic rhinoconjunctivitis.
It said the primary endpoint was the safety and tolerability of seven injections of Acarovac MPL administered over six to 12 weeks, each one or two weeks apart.
The formulation was said to have been \"well-tolerated\", with the safety profile described as \"satisfactory\" and the reported adverse events consistent with what had been observed with similar formulations of allergy vaccines.
Secondary endpoints included the effect of treatment on response to nasal provocation test, immunological parameters including immunoglobulins, and patient satisfaction with the treatment.
A \"significant\" improvement from baseline in patients\' total symptom scores following the nasal provocation test after 12 weeks, and \"significant\" increases in immunoglobulin markers and reduction in IL-4, were observed.
Patients reported high satisfaction with their treatment measured via the ESPIA questionnaire, the board added.
\"The success of our clinical trial in house dust mite-induced allergic rhinitis is encouraging news for the many patients who continue to suffer with the symptoms caused by house dust mite allergy, and supports our ambition to provide a global therapy for the important US, China and EU markets,\" said Allergy Therapeutics chief executive officer Manuel Llobet.
\"Based on the unique triple-combination of our allergoids, and the adjuvant system MPL and MCT we believe Acarovac MPL could build on our success in dust mite immunotherapy and we look forward to progressing towards phase II clinical studies.\"
The company described Acarovac MPL as a subcutaneous immunotherapy product containing dermatophagoides pteronyssinus and dermatophagoides farinae allergoids, adsorbed to the adjuvant system comprised of \'MCT\' (microcrystalline tyrosine) and MPL.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN